Eclipse TMR Laser Gains Panel Approval Despite 5% Overall Mortality Rate
This article was originally published in The Gray Sheet
Executive SummaryEclipse Surgical should meet with FDA to develop a postmarket study for the Eclipse 2000 transmyocardial revascularization laser system for treatment of patients with Class IV angina refractory to medical treatment, FDA's Circulatory System Devices Panel concluded at an Oct. 27 meeting.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.